Confirmatory Trials: Flexibility In Timing Hinges On Accelerated Approval Indication Size – FDA’s Marks

 
• By Sue Sutter
balance beam
CBER will consider regulatory flexibility for rare diseases when it comes to confirmatory trial timelines. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards